NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
The biopharmaceutical company is using its biologically-guided exosome therapy ExoTherapy platform to expand its portfolio of products that will address spinal cord injuries and regeneration of neurons in other CNS indications.
- The biopharmaceutical company is using its biologically-guided exosome therapy ExoTherapy platform to expand its portfolio of products that will address spinal cord injuries and regeneration of neurons in other CNS indications.
- In the latest development, NurExone has developed two selective small inhibiting RNA sequences (siRNA) that target and inhibit proteins within the Peri-Neural Network (PNN) complex (Fig.
- The breakthrough sequences, detailed in a patent application held by the Company, are built upon a scientifically validated strategy for enhanced neuronal regeneration via inhibition of the PNN complex.
- The Company believes that its innovative approach, using the Company’s ExoTherapy platform to deliver these RNA sequences, will overcome limitations of previous methods.